Boehringer To Acquire Trutino Under Aggressive Cancer R&D Strategy

Remains Mum On Numbers

The family-owned German firm plans to purchase all shares of current partner, Trutino, to gain its systematically delivered cytokine portfolio amid a broader push to diversify and improve its oncology offering.    

Boehringer's Recent Deals Have Focused On Precision Cancer Medicines • Source: Shutterstock

Boehringer Ingelheim GmbH has signed an option to acquire partner Trutino Biosciences, Inc. for its next-generation ‘on-demand’ cytokine platform, marking its second deal this month aimed at bulking up its oncology pipeline.

Boehringer has retained the right to buy all shares of Trutino upon the completion of certain program milestones within a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.